The importance of the posttranscriptional regulation of gene expression has been driven home in the last few years, as it is now known that the vast number of proteins thought to comprise the human proteome are generated from a much smaller number of genes (16) . Pre-mRNA alternative splicing is an important mechanism for the generation of protein diversity (14) . It is currently estimated that 60 to 74% of human genes undergo alternative splicing (17, 18) . Tight regulation of alternative splicing is necessary for the appropriate temporal and spatial control of gene expression, and disruption of splicing regulation can cause or contribute to human disease (11) .
Members of the CUG binding protein (CUG-BP) and the embryonic lethal abnormal vision type RNA binding protein 3 (ETR-3)-like factor (CELF) family of RNA binding proteins (also called BRUNOL proteins) regulate alternative splicing by binding to intronic elements within specific pre-mRNA targets (7, 10, 19, 21, 35, 38) . Two CELF proteins, CUG-BP1 (also known as BRUNOL2) and ETR-3 (also known as BRUNOL3, CUG-BP2, or NAPOR), are expressed in the heart and are hypothesized to drive changes in alternative splicing during cardiac development (22) . CUG-BP1 and ETR-3 have also been suggested to play key roles in the pathogenesis of a number of disorders in heart and skeletal muscle, including myotonic dystrophy, Duchenne and Becker muscular dystrophies, partial monosomy 10p, and familial arrhythmogenic right ventricular dysplasia (7, 23, 24, 35, 38, 40) . These reports suggest an important role for CELF-mediated alternative splicing regulation in the myocardium.
We previously described CELF⌬, a truncated form of CELF4 (also known as BRUNOL4) that acts as a dominant negative to specifically repress the alternative splicing activity of the members of the CELF family in cultured cells without globally disrupting alternative splicing (6) . Transient expression of CELF⌬ in primary embryonic cardiomyocyte cultures demonstrated that endogenous CELF activity is required for the appropriate alternative splicing of CELF targets in heart muscle cells (22) . To determine the role of CELF-mediated alternative splicing regulation in the heart in vivo, we generated transgenic mice that express CELF⌬ specifically in the heart by using the ␣-myosin heavy chain promoter. A dominant-negative approach was chosen in lieu of a more traditional knockout approach for two reasons. First, in transienttransfection assays, CUG-BP1 and ETR-3 have very similar effects on the alternative splicing of known CELF target premRNAs (10, 19) , suggesting that these proteins have a high degree of functional redundancy. Second, both CUG-BP1 and ETR-3 are expressed in the cytoplasm as well as the nucleus in the heart (22) and several reports have implicated CELF proteins in the regulation of cytoplasmic RNA processing events, including deadenlyation and translation (12, 28, (32) (33) (34) 41) . In knockout mice, it would be difficult to distinguish between the effects from loss of nuclear versus cytoplasmic CELF functions. Overexpression of a nuclear dominant-negative protein allows us to overcome both of these obstacles: we can repress the activity of all CELF proteins expressed in the heart, and we can target repression specifically to the nucleus, where splicing takes place.
Here, we report a striking cardiac phenotype in mice attributable to the inhibition of CELF splicing activity by the cardiac tissue (MHC-CELF⌬)-specific expression of a dominant-negative CELF protein. Animals expressing the MHC-CELF⌬ transgene develop early-onset cardiac hypertrophy and dilated cardiomyopathy characterized by fibrosis, changes in gene ex-pression associated with heart failure, severe cardiac dysfunction, and premature death. MHC-CELF⌬ mice exhibit specific defects in the alternative splicing of pre-mRNA targets of CELF-mediated regulation, and both the splicing defects and gross pathological changes are rescued by the increased cardiac expression of CUG-BP1, a wild-type CELF protein. Our results indicate that CELF-mediated alternative splicing regulation is necessary for maintenance of normal cardiac structure and function.
normalized against levels of glyceraldehyde-2-phosphate dehydrogenase (GAPDH) expression using the formula 2 to the power of [(number of cycles to reach set level of GAPDH) -(number of cycles to reach set level of marker gene)], setting the level for comparison within the linear range of amplification for all genes.
Statistics. Data are reported as means Ϯ standard errors of the means unless otherwise noted. Comparisons between groups were performed by analysis of variance with post hoc testing (Tukey) using SPSS software or with two-tailed t tests using Microsoft Excel. Differences were considered statistically significant at a P of Յ0.05.
RESULTS
MHC-CELF⌬ mice exhibit defects in CELF-mediated alternative splicing. CELF⌬ is approximately 35 kDa, well below the size limit for passive diffusion through the nuclear pore complex (13, 30) . To drive the localization of CELF⌬ to the nucleus, where alternative splicing takes place, the simian virus 40 large T antigen nuclear localization signal was inserted in frame between the N-terminal epitope tag and the CELF⌬ open reading frame to create NLSCELF⌬. In transfected cells, NLSCELF⌬ is detectable only in the nucleus and represses the activity of the CELF family in a manner similar to the original CELF⌬ (data not shown). To create mice that express this nuclear dominant-negative protein in the heart, a transgene was created (MHC-CELF⌬) (Fig. 1A ) in which the expression of NLSCELF⌬ is driven by the mouse ␣-myosin heavy chain (␣-MHC) promoter.
Three transgenic founders with germ line transmission were obtained (MHC-CELF⌬-10, -11, and -574). The MHC-CELF⌬-11 F 0 female died from a postpartum uterine infection, however, and her line was subsequently lost. The only transgenic pup obtained from the MHC-CELF⌬-11 line died 10 days following birth, and dissection followed by Western blotting revealed an enlarged heart that expressed high levels of the transgene protein (Fig. 1B and data not shown) . Transgenic animals from line MHC-CELF⌬-10 survived to maturity and expressed the NLSCELF⌬ protein, though at levels lower than the pup from line MHC-CELF⌬-11 (Fig. 1B) . The third line, MHC-CELF⌬-574, expressed the lowest levels of NLSCELF⌬ of the three lines (data not shown). Except where otherwise noted, analyses were conducted on line MHC-CELF⌬-10, the higher expressing of the two surviving lines.
To confirm that the alternative splicing activity of the CELF family is disrupted in MHC-CELF⌬ mice, the alternative splicing pattern of the myotubularin-related protein 1 (Mtmr1) transcripts in MHC-CELF⌬ hearts was compared to that of wild-type littermates at different ages. The Mtmr1 gene has two alternative exons (2.1 and 2.2) that are alternatively spliced to give rise to three mRNA isoforms (Fig. 1C) and was recently identified as a target of CELF-mediated splicing regulation in humans, following a genomic screen for intronic sequences that contain U/G-rich motifs characteristic of CELF binding sites (10) . Mtmr1 alternative splicing is conserved between mouse and human (5) , and the mouse Mtmr1 gene also contains putative CELF binding sites in the introns adjacent to the alternative exons (see Table S1 in the supplemental material). The C isoform, which includes both alternative exons, predominates in the wild-type heart (Fig. 1C) . In the transgenic heart, Mtmr1 alternative splicing was unperturbed at birth. By 3 weeks, however, there was a marked reduction in the amount of the C isoform in MHC-CELF⌬ hearts, with a corresponding 2, which may be alternatively spliced such that they are both included (isoform C), only the first is included (isoform B) or both are skipped (isoform A). In the wild-type heart, the C isoform predominates in newborn and 3-week-old animals. In the transgenic heart, Mtmr1 alternative splicing is normal at birth but by 3 weeks, the C isoform is diminished and the B isoform is induced. VOL. 25, 2005 CELF ACTIVITY REQUIRED FOR CARDIAC FUNCTION 6269 increase in the B isoform, which includes the 2.1 exon but skips the 2.2 exon (Fig. 1C ). This suggests that for Mtmr1 splicing in the heart, CELF activity is important for the inclusion of exon 2.2. We hypothesized that the expression of NLSCELF⌬ would specifically disrupt the alternative splicing of CELF target premRNAs in vivo without globally disrupting alternative splicing. To confirm this, we identified three other putative CELF targets and four putative nontargets and compared their alternative splicing patterns in wild-type and MHC-CELF⌬ hearts. Candidate targets contained U/G-rich motifs that could act as CELF binding sites in one or both introns adjacent to an alternatively spliced exon, whereas putative nontargets lacked any motifs resembling CELF binding sites in the flanking introns (see Table S1 in the supplemental material). At 3 weeks, all three of the putative targets identified showed different ratios of their alternative splice forms in MHC-CELF⌬ hearts relative to the wild type whereas none of the four putative nontargets were affected (Fig. 2) .
MHC-CELF⌬ transgenic mice develop early-onset cardiac hypertrophy and dilated cardiomyopathy. Hemizygous MHC-CELF⌬ mice appeared normal at birth and were obtained at the expected Mendelian frequency. Attempts to generate homozygous MHC-CELF⌬ mice failed, however, as the female transgenic mice did not tolerate pregnancy. From 16 F 1 sibling crosses, eight females died during pregnancy, five died within a few days of delivery, one became severely distressed during pregnancy and was euthanized, and one failed to become pregnant. The females that died ranged from 8.5 to 16.5 weeks old, and all exhibited dramatic cardiac hypertrophy. The heart comprised 1.59% Ϯ 0.12% of the body weight in the transgenic females that died (n ϭ 11), almost three times that of agematched, normal female littermates sacrificed for comparison (0.62% Ϯ 0.06%, n ϭ 6). Because normal littermates were virgins with lower body weights than their transgenic pregnant/ postpartum counterparts (for pregnant females, body weights include unborn pups), this difference is likely to be underestimated. All subsequent data presented in this study are derived from hemizygous, nonparous animals.
Cardiac hypertrophy in MHC-CELF⌬ animals is not pregnancy dependent. Figure 3A shows the heart of a virgin 8-week-old MHC-CELF⌬ female compared to that of her wild-type littermate. Coronal sections revealed mild cardiac enlargement that is primarily left sided with a globular left ventricular contour at 3 weeks following birth (Fig. 3B ). At 9 weeks, transgenic hearts were more strikingly enlarged, exhibiting expansion of the chambers but without dramatic wall thinning, indicating both cardiac hypertrophy and dilation (Fig.  3C ). Left atrial dilation was present at both 3 and 9 weeks of age, with thrombosis of the chamber at 9 weeks (Fig. 3C) .
To characterize the progression of hypertrophy, the heart sizes of MHC-CELF⌬ mice and their wild-type littermates were measured over a postnatal time course ( Fig. 3D and E). Heart size was evaluated as the percentage of total body weight that is heart weight. This method was deemed valid because no differences were observed between the mean body weights of nonparous transgenic animals and their sex-matched wild-type littermates at any age evaluated (data not shown). Although there was considerable overlap in heart sizes between individuals in the wild-type and transgenic populations at 3 weeks, some individuals had slightly enlarged hearts ( Fig. 3D) and there was already a small but significant increase in the mean heart sizes of female MHC-CELF⌬ mice relative to their wildtype counterparts (Fig. 3E) . By 6 weeks, cardiac hypertrophy was pronounced in transgenic males and females, and by 9 weeks, MHC-CELF⌬ hearts reached their maximum mean size. It is interesting to note that the mean heart size of the transgenic males was not increased as much as that of transgenic females (see "Phenotypic penetrance is lower in MHC-CELF⌬ males than females" below). The same differences Table S1 in the supplemental material). The alternative splicing patterns of three putative targets were found to differ between the hearts of female wild-type and MHC-CELF⌬ littermates at 3 weeks of age by RT-PCR. (B) Several alternatively spliced mouse genes that lack U/G-rich motifs resembling CELF binding sites in the introns adjacent to their alternative exons were also identified and were designated putative nontargets. The splicing patterns of four of these putative nontargets were identical in the hearts of 3-week-old wild-type and MHC-CELF⌬ female littermates. Two or more individuals were evaluated for each putative target or nontarget with similar results. A representative example for each is shown. WT, wild type; TG, transgenic. between groups were seen when heart size was measured as a ratio of heart weight to tibia length (data not shown). The development of cardiac hypertrophy is not due to the disruption of another gene at the integration site but depends on expression of the NLSCELF⌬ protein. Just as the animal from the MHC-CELF⌬-11 line had severe hypertrophy and early death associated with very high levels of NLSCELF⌬ expression, animals from the MHC-CELF⌬-574 line, which express the lowest levels of NLSCELF⌬ protein, likewise develop cardiac hypertrophy that is less severe than that seen in the other lines. The mean heart size of MHC-CELF⌬-574 females at 9 weeks was 0.65% Ϯ 0.02% of the body weight (n ϭ 15), significantly greater than the 0.52% Ϯ 0.01% of body weight (n ϭ 34) observed for agematched wild-type females (P Յ 0.05).
Phenotypic penetrance is lower in MHC-CELF⌬ males than females. Premature death was commonly observed in MHC-CELF⌬ animals. In the vast majority of cases, individuals appeared healthy and did not show overt signs of poor health (such as weight loss or lethargy) prior to death. Survival curves were plotted for transgenic mice out to 24 weeks of age (Fig.  4A) . Strikingly, 91% of MHC-CELF⌬ males but only 27% of MHC-CELF⌬ females were still alive at 24 weeks of age. This is a dramatic increase in mortality in female mice, as the average life span of wild-type FVB mice in our vivarium is approximately 2 years (C. Beverly and J. Bondzinski, Baylor College of Medicine Center for Comparative Medicine, personal communication).
This difference in survival is not the only difference observed between the sexes in the MHC-CELF⌬ population. As mentioned above, the mean heart size of transgenic males is not elevated as much as in transgenic females at any age (Fig. 4B) .
In fact, the hearts of many MHC-CELF⌬ males remained unaffected. No more than 50% of MHC-CELF⌬ males developed cardiac hypertrophy within the first 24 weeks, far fewer than MHC-CELF⌬ females, 85% of whom developed hypertrophy by 6 weeks (Fig. 4B ). This disparity is also seen between   FIG. 4 . Penetrance of the MHC-CELF⌬ phenotype is lower in males than in females, despite similar amounts of NLSCELF⌬ protein expression. (A) Survival. Mortality is dramatically higher for MHC-CELF⌬ females than males. The number of animals in each group is indicated. (B) Incidence of hypertrophy. By 6 weeks after birth, more than 80% of MHC-CELF⌬ females have cardiac hypertrophy, whereas the incidence of hypertrophy remains low in transgenic males. An individual is considered to have cardiac hypertrophy if its heart is larger than 2 standard deviations above the mean heart size of sex-and age-matched wild-type mice. The number of animals in each group is indicated. (C) Splicing defects. All transgenic females, but only two-thirds of transgenic males have defects in Mtmr1 alternative splicing in the heart at 3 weeks of age. (D) NLSCELF⌬ protein expression. Western blot probed with an antibody against the N-terminal Xpress epitope tag reveals similar levels of NLSCELF⌬ expression in the hearts of male and female littermates at 6 weeks of age. From this litter, two of the three transgenic females but none of the transgenic males had pronounced cardiac hypertrophy. Fifty micrograms of total protein lysate was loaded per lane, and equivalent loadings were confirmed by Ponceau S staining (data not shown).
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the sexes in the lower-expressing MHC-CELF⌬-574 line, as 60% of females but only 18% of males developed mild hypertrophy by 9 weeks (data not shown). The observed differences between males and females are also evident at the level of alternative splicing. All of the female MHC-CELF⌬ mice evaluated displayed defective Mtmr1 splicing by 3 weeks, but only a portion of the MHC-CELF⌬ males exhibited splicing patterns that differed from the wild type (Fig. 4C) . The dissimilar penetrance of the phenotype between MHC-CELF⌬ males and females is not attributable to a difference in expression of the transgene. Western blot analysis demonstrated similar levels of NLSCELF⌬ expression in male and female transgenic littermates, regardless of the presence or absence of cardiac hypertrophy in these individuals (Fig. 4D) . Intriguingly, these results suggest that there is a sex-specific modulation of CELF-mediated alternative splicing activity.
MHC-CELF⌬ transgenic mice exhibit severe pathology and cardiac dysfunction. To characterize the health of the transgenic heart, we performed histological analysis on hearts from wild-type and MHC-CELF⌬ females. Four days following birth, there were no pronounced differences between transgenic and wild-type hearts (data not shown). At 3 weeks following birth, trichrome staining revealed early fibrosis and myocyte degenerative changes, as evidenced by paler fibers indicative of myocytolysis (Fig. 5A) . At 9 weeks, degenerative myocytolysis was more extensive, with continuing loss of myofibers and fibrosis (Fig. 5B) . In addition to the evident cardiac damage, by 9 weeks, we saw secondary signs of cardiac dysfunction in the lungs of affected MHC-CELF⌬ animals. Grossly, lungs looked gray and swollen (data not shown). Wet lung weights of MHC-CELF⌬ females were more than twice those of age-and sex-matched wild-type littermates (283 Ϯ 18 mg versus 131 Ϯ 5 mg; n ϭ 6 each). Trichrome-stained sections of lungs revealed dilated veins with muscular hypertrophy of the wall, indicative of chronically elevated left-ventricular-end diastolic pressure (Fig. 5C ). The thrombosis observed in the dilated left atrium of the 9-week-old MHC-CELF⌬ heart is also consistent with chronic left-heart dysfunction (Fig. 3C) .
To determine whether MHC-CELF⌬ mice were undergoing heart failure, we used real-time RT-PCR analysis to measure the expression levels of three genes known to be upregulated in the failing heart: atrial natriuretic factor, B-type natriuretic peptide, and ␣-skeletal actin (4, 36). All three of these markers were upregulated in MHC-CELF⌬ hearts by 3 weeks (see Fig.  S1 in the supplemental material), prior to the onset of severe hypertrophy but consistent with the onset of splicing defects and the presence of scarring in the heart at this age ( Fig. 1C  and 5A ). Cardiac function in female MHC-CELF⌬ mice was compared to age-and sex-matched wild-type littermates using Mmode echocardiography and 10-mHz Doppler ultrasound. At 4 to 5 days following birth, the cardiac function of transgenic mice was indistinguishable from that of wild-type littermates when assessed by Doppler (data not shown). At 9 weeks, however, MHC-CELF⌬ mice had profound cardiac dysfunction ( Fig. 6 and Table 1 ). Under anesthesia, the transgenic mice had normal heart rates with no sign of persistent arrhythmia ( Table 1 ). The beat-to-beat variability as measured by the standard deviation of the RR interval measuring the time between the R peaks in the electrocardiogram was also not different from the wild type (Table 1 ). Echocardiography confirmed that the left ventricles of the transgenic heart were enlarged without thinning of the ventricular wall (Fig. 6A) . The end diastolic and end systolic dimensions were both significantly increased in MHC-CELF⌬ hearts ( Fig. 6 and Table  1 ). Some transgenic individuals also had a detectable increase in the thickness of the posterior wall, though the mean posterior wall thickness of transgenic hearts was not statistically different from that of the wild type (Table 1) . Fractional shortening, an indicator of systolic function, was severely reduced in the transgenic heart, indicating impaired contraction. Doppler analysis confirmed poor systolic function. The peak aortic flow velocity and mean and peak aortic accelerations were significantly reduced in MHC-CELF⌬ animals, whereas the isovolumic contraction time was significantly elevated ( Table 1) . Diastolic dysfunction was also evident. The peak early-filling velocity was reduced, whereas the isovolumic relaxation time and Tei index were both significantly increased in transgenic animals (Table 1) . Interestingly, there was no easily discernible A wave on the transmitral Doppler in five out of the six MHC-CELF⌬ mice evaluated, indicating that despite the presence of a clear electrical activation of the atria (see P waves on the electrocardiogram), there was no significant atrial contribution to left-ventricular filling (Fig. 6B) . Together, these results show that MHC-CELF⌬ mice have enlarged hearts that exhibit both ventricular wall thickening and dilation and have a severe systolic and diastolic defect.
The MHC-CELF⌬ phenotype is rescued by the overexpression of CUG-BP1 in the heart. It is possible that the overexpression of exogenous NLSCELF⌬ in the heart causes pathogenesis by a mechanism unrelated to its effects on CELFmediated splicing. CELF⌬ does not bind to RNA (39) , making it unlikely that the effects on the splicing of CELF targets are due to a gain-of-function of the NLSCELF⌬ protein acting directly on RNA. Both the defects in Mtmr1 alternative splicing and the development of cardiac hypertrophy occur with similar incidences in MHC-CELF⌬ males, which supports the hypothesis that pathology in the transgenic heart can be attributed to the disruption of normal CELF-mediated alternative splicing. To confirm this hypothesis, we crossed MHC-CELF⌬ males to female mice that overexpress CUG-BP1 in heart and skeletal muscle under the control of the muscle creatine kinase promoter (MCKCUG-BP). If the observed pathology in MHC-CELF⌬ mice is in fact due to the repression of CELF activity, the effects should be alleviated in double-transgene offspring by the increase in wild-type CELF protein. Characterization of MCKCUG-BP mice is described in a separate report (15a) . In the line of MCKCUG-BP mice used for these experiments, MCKCUG-BP-1036, transgenic animals overexpressed less than twofold the amount of endogenous CUG-BP1 protein found in the hearts of wild-type animals at 9 weeks (data not shown). Bitransgenic females were evaluated at 9 weeks, since a high proportion of MHC-CELF⌬ females are affected and mean heart size has reached its peak level by this age (Fig. 3) . Overexpression of CUG-BP1 partially rescued the effects of the dominant-negative protein but, alone, had no effect on heart size or survival compared to wild-type animals (Fig. 7) . The mean heart size in MHC-CELF⌬/MCKCUG-BP double-transgene females was significantly smaller than that for MHC-CELF⌬ females alone, although still greater than that of wild-type females (Fig. 7A) . Likewise, the percentage of females that had cardiac hypertrophy was lower (Fig. 7B) and a greater fraction of MHC-CELF⌬/MCKCUG-BP females survived to 9 weeks (Fig. 7C) .
To confirm that CUG-BP1 overexpression restores CELFmediated alternative splicing in the MHC-CELF⌬ heart, Mtmr1 splicing patterns were determined by RT-PCR analysis (Fig. 7D) . In wild-type mice at 9 weeks, the C isoform predominated. The predominance of the C isoform was not affected by the overexpression of CUG-BP1 alone in the MCKCUG-BP-1036 line. In MHC-CELF⌬ hearts at 9 weeks, however, the ratio of the C and B isoforms was approximately 50/50. Again, this suggests that CELF activity is important for inclusion of the second alternative exon. Inclusion of this exon improved in MHC-CELF⌬/MCKCUG-BP hearts as the C to B ratio was increased, though the proportion of total transcripts that were the C isoform was not completely restored to wildtype levels. Together, these results verify that defects in CELFmediated splicing and the overt cardiac pathology in MHC-CELF⌬ mice are both the result of reduced CELF activity in the hearts of these animals.
DISCUSSION
The present study demonstrates that CELF protein activity is critical for the appropriate alternative splicing of CELF targets in the heart in vivo and that normal CELF-mediated alternative splicing regulation is necessary for healthy cardiac function. It is important to note that ␣-MHC is transiently down-regulated in the ventricles during embryogenesis (27) , so the MHC-CELF⌬ transgene, which drives the expression of NLSCELF⌬ under the control of the ␣-MHC promoter, would be expected to reach its highest level of expression and therefore its greatest efficacy shortly after birth. This is consistent with the onset of the MHC-CELF⌬ phenotype. By all measures (alternative splicing patterns, histology, and functional tests), MHC-CELF⌬ mice are indistinguishable from wild-type animals in the first 4 days after birth. By 3 weeks after birth, however, MHC-CELF⌬ mice exhibit defects in alternative splicing, changes in gene expression, and scarring in the heart, and by 9 weeks, overt differences are observed in cardiac size and function.
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demonstrate the harmful effects of perturbing factors that regulate alternative splicing in the heart. Cardiac-specific loss of SC35 or ASF/SF2 causes dilated cardiomyopathy (8, 43) . For ASF/SF2, loss leads to the aberrant regulation of CaMKII‫ץ‬ alternative splicing and overexpression of the inappropriate CaMKII‫ץ‬ splice form recapitulates the phenotype of ASF/SF2 ablation (43) . In this report, reduced CELF activity in the hearts of MHC-CELF⌬ mice was shown to affect the splicing of a natural pre-mRNA target, Mtmr1 (10), as well as the three putative CELF targets myocyte enhancer factor 2A (Mef2A), ␤1 integrin, and bridging integrator 1 (Bin1). With the exception of ␤1 integrin, the specific functional consequences of these alternative splicing events are unknown but these genes participate in diverse cellular functions that could contribute to pathogenesis. MTMR1 belongs to a family of phosphatases, and although its substrates are not known, aberrant ratios of Mtmr1 splice forms have been proposed to contribute to striated muscle defects in myotonic dystrophy (5, 15a) . Mef2A belongs to a family of transcription factors critical for cardiogenesis that are involved in mediating the development of hypertrophic features in cardiac hypertrophy (1) . Inclusion of the alternative exon D of ␤1 integrin alters the cytoplasmic domain of this cell-surface receptor and strengthens cytoskeleton-matrix linkages in muscle cells (3) . Knockout of exon D in mice caused the increased expression of markers of ventricular dysfunction, suggesting that the increased adhesion of ␤1 integrin provided by the inclusion of exon D is important for cardiac contraction (2). Bin1 is an adaptor protein and putative tumor suppressor that is required in cardiac muscle (29) . Though its precise function is not known, inclusion of the alternative exon 10 has been suggested to control its subcellular localization and is associated with impeded proliferation in cultured skeletal muscle cells (42) . Additional targets that have not yet been identified may also be misspliced in the transgenic heart. Given that we have observed changes in alternative splicing for several pre-mRNAs, we feel that it is unlikely that the alternative splicing of any single target is fully responsible for the pathology in MHC-CELF⌬ mice. Rather, it seems likely that the combined effects on the subset of CELF targets contribute to the observed cardiac dysfunction and pathology. Several targets of CELF regulation have been identified in skeletal muscle, and misregulation of these different CELF targets in the muscles of myotonic dystrophy patients is thought to explain distinct symptoms of the disease (7, 35, 38) . MHC-CELF⌬ mice will provide a useful tool in future studies to help delineate programs of CELF-mediated alternative splicing regulation in the heart. Although the full complement of affected targets has not been elucidated, it is clear that the pathology observed in MHC-CELF⌬ hearts can be attributed to a reduction in CELF splicing activity rather than an unrelated gain-of-function of the dominant-negative protein, as overexpression of CUG-BP1 in the hearts of these animals at least partially rescues both the splicing defects of the known target Mtmr1 and the overt signs of cardiac disease. The double-transgene animals overexpressing the dominant-negative protein and wild-type CUG-BP1 are not completely restored to a wild-type phenotype, however, perhaps because the levels of CUG-BP1 are insufficient to fully compensate for the extent of repression by NLSCELF⌬. The MCKCUG-BP-1036 line used for these experiments expresses levels of CUG-BP1 only slightly above normal endogenous levels in the first few weeks after birth. A second line that had similar levels of CUG-BP1 overexpression, MCKCUG-BP-1032, showed a similar level of rescue when crossed with MHC-CELF⌬ animals (data not shown). Another possible explanation for the incomplete restoration of wild-type phenotype in the double-transgene animals is that we are only adding back a single CELF protein. ETR-3 is also expressed in the heart (19, 21, 22) and may exert some effects on splicing that do not overlap with CUG-BP1. Although CUG-BP1 and ETR-3 are highly conserved (the human proteins are 78% identical), they may interact with different subsets of transcripts or different protein partners to form distinct splicing complexes on their target RNAs. To date, their activities have been compared on only a few targets, predominantly by transient transfection assays in which the proteins are highly overexpressed (10, 19, 39) . It would be interesting in the future to compare the effects of knocking out CUG-BP1 and ETR-3 activities independently.
The most surprising finding in this study was the pronounced phenotypic disparity between males and females despite similar levels of transgene expression. It is not uncommon for genetically modified mice to display sex differences in cardiac phenotypes, but in most cases, females fare better than males, with lower mortality, less severe hypertrophy, and mitigated pathology (9) . MHC-CELF⌬ mice are unusual because males are less likely than their female counterparts to exhibit splicing defects, develop cardiac hypertrophy, or die young. There are several possibilities that could explain the sex differences in MHC-CELF⌬ mice. Males may have a greater tolerance for the misexpression of CELF-regulated splice variants than females. Alternatively, there may be female-specific pre-mRNA targets of CELF activity that contribute to the onset of pathogenesis or male-specific targets that offer some protective effect. The fact that there is a difference in penetrance not only for the gross features of the phenotype but also for Mtmr1 splicing suggests that there is a sex-specific modulation at the level of CELF splicing activity. It is not known what protein partners the CELF proteins require or what posttranslational modifications are important for their activity. Sex-specific differences in expression or activity of a cofactor or modifier could create differences in the levels of CELF activity between b Vcfc, rate-corrected mean velocity of circumferential fiber shortening ϭ (fractional shortening ϫ square root of the RR interval)/ejection time.
c Tei index ϭ (isovolumic contraction time ϩ isovolumic relaxation time)/ ejection time.
males and females. Sex-specific alternative splicing has been well described in Drosophila melanogaster, where the sex-specific expression of alternative splicing regulators controls sex determination (26) . In vertebrates, tra2␣, the mammalian homolog of a Drosophila splicing regulator, is upregulated in response to androgen stimulation (25) . Emerging evidence also links levels of sex hormones to sex differences in cardiac pathology seen in mice (10) . Sex-specific differences in cardiac CELF protein expression, modification, activity, and response to sex hormone pathways are now being investigated. The mean heart sizes Ϯ the standard errors of the means are shown for nonparous female animals at 9 weeks of age. The number of animals in each group is indicated. An asterisk indicates that the mean is significantly different from that of the wild type, and a caret indicates that the mean is significantly different from that of MHC-CELF⌬ alone (P Յ 0.05). (B) The female population overexpressing wild-type CUG-BP1 and NLSCELF⌬ exhibits a lower incidence of cardiac hypertrophy than transgenic females that express the dominant-negative protein alone. Cardiac hypertrophy is defined as the heart size more than 2 standard deviations above the mean heart size of sex-and age-matched wild-type mice. (C) Overexpression of CUG-BP1 in the heart improves the survival rate of females expressing the dominant-negative protein. (D) At 9 weeks, the C isoform of Mtmr1 is the predominant splice form in wild-type mice. In MHC-CELF⌬ mice, the C isoform is reduced and the level of the B isoform is elevated. Overexpression of CUG-BP1 increases the proportion of the C isoform. 
